Claire Nollett

Claire Nollett

Auto-generated profile, based on publicly available information

Claire Nollett

Centre for Vision Services Research, Cardiff University, Cardiff, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Ophthalmology
Verified
Journal Article
Open access
CNClaire L. Nollett
Claire L. Nollett
NBNathan Bray
Nathan Bray
CBCatey Bunce
Catey Bunce
RCRobin J. Casten
Robin J. Casten
RERhiannon T. Edwards
Rhiannon T. Edwards
TMTom H. Margrain
Tom H. Margrain

1 August 2016 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
CNClaire L. Nollett
Claire L. Nollett
NBNathan Bray
Nathan Bray
CBCatey Bunce
Catey Bunce
RCRobin J. Casten
Robin J. Casten
RERhiannon T. Edwards
Rhiannon T. Edwards
TMTom H. Margrain
Tom H. Margrain
Purpose: The purpose of this study was to compare two interventions for depression, problem solving treatment (PST) and referral to the patient's physician, with a waiting-list control group in people with sight loss and depressive symptoms. Methods: This was an assessor-masked, exploratory, multicenter, randomized clinical trial, with concurrent economic analysis. Of 1008 consecutive attendees at 14 low-vision rehabilitation centers in Britain, 43% (n = 430) screened positive for depressive symptoms on the Geriatric Depression Scale and 85 of these attendees participated in the trial. Eligible participants were randomized in the ratio 1:1:1 to PST, referral to their physician, or a waiting-list control arm. PST is a manualized talking intervention delivered by a trained therapist who teaches people over six to eight sessions to implement a seven-step method for solving their problems. Referral to the physician involved sending a referral letter to the person's physician, encouraging him or her to consider treatment according to the stepped care protocol recommended by the U.K.'s National Institute of Health and Care Excellence. The primary outcome was change in depressive symptoms (6 months after baseline) as determined by the Beck Depression Inventory. Results: At 6 months, Beck Depression Inventory scores reduced by 1.05 (SD 8.85), 2.11 (SD 7.60), and 2.68 (SD 7.93) in the waiting-list control, referral, and PST arms, respectively. The cost per patient of the PST intervention was £1176 in Wales and £1296 in London. Conclusions: Depressive symptoms improved most in the PST group and least in the control group. However, the change was small and the uncertainty of the measurements relatively large.

31 May 2024 in Research Involvement and Engagement
Verified
Journal Article
Open access
PDF file
CNClaire Nollett
Claire Nollett
MEMatthias Eberl
Matthias Eberl
JFJim Fitzgibbon
Jim Fitzgibbon
NJNatalie Joseph-Williams
Natalie Joseph-Williams
SHSarah Hatch
Sarah Hatch
Background: Involving and engaging the public in scientific research and higher education is slowly becoming the norm for academic institutions in the United Kingdom and elsewhere. Driven by a wide range of stakeholders including regulators, funders, research policymakers and charities public involvement and public engagement are increasingly seen as essential in delivering open and transparent activity that is relevant and positively impacts on our society. It is obvious that any activities involving and engaging members of the public should be conducted safely and ethically. However, it is not clear whether conducting activities ethically means they require ethical approval from a research ethics committee. Main body: Although there is some guidance available from government organisations (e.g. the UK Health Research Authority) to suggest ethical approval is not required for such activities, requests from funders and publishers to have ethical approval in place is commonplace in the authors’ experience. We explore this using case studies from our own institution. Conclusion: We conclude that any public-facing activity with the purpose to systemically investigate knowledge, attitudes and experiences of members of the public as research and as human participants requires prior approval from an ethics committee. In contrast, engaging and involving members of the public and drawing on lived experience to inform aspects of research and teaching does not. However, lack of clarity around this distinction often results in the academic community seeking ethical approval ‘just in case’, leading to wasted time and resources and erecting unnecessary barriers for public involvement and public engagement. Instead, ethical issues and risks should be appropriately considered and mitigated by the relevant staff within their professional roles, be it academic or a professional service. Often this can involve following published guidelines and conducting an activity risk assessment, or similar. Moving forward, it is critical that academic funders and publishers acknowledge the distinction and agree on an accepted approach to avoid further exacerbating the problem.

17 January 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
CNClaire Nollett
Claire Nollett
BRBarbara Ryan
Barbara Ryan
NBNathan Bray
Nathan Bray
CBCatey Bunce
Catey Bunce
RCRobin Casten
Robin Casten
TMTom H Margrain
Tom H Margrain
Objective To identify the risk factors for significant depressive symptoms in people with visual impairment in England and Wales to provide information on who is most at risk and to whom support services could be targeted in future. Design A cross-sectional study using baseline data from a pragmatic randomised controlled trial. Setting and participants 990 participants aged 18 or over attending 1 of 14 low-vision rehabilitation primary care optometry-based clinics in South Wales or two hospital clinics in London. Outcome measure A score of ≥6 on the Geriatric Depression Scale-15 was classed as clinically significant depressive symptoms. Results In a multivariable logistic regression model, significant depressive symptoms were associated with age (adjusted OR (AOR)=0.82, 95% CI: 0.66 to 0.90, p<0.001), ethnicity (AOR non-white compared with white=1.72, 95% CI: 1.05 to 2.81, p=0.031), total number of eye conditions (AOR for two vs one condition=0.98, 95% CI: 0.67 to 1.43; three or more vs one condition=0.34, 95% CI: 0.15 to 0.75, p=0.026), self-reported health (AOR for excellent vs poor=0.01, 95% CI: 0.00 to 0.12; very good vs poor=0.06, 95% CI: 0.03 to 0.13; good vs poor=0.14, 95% CI: 0.08 to 0.24; fair vs poor=0.28, 95% CI: 0.18 to 0.46, p<0.001) and self-reported visual functioning (AOR=1.45, 95% CI: 1.31 to 1.61, p<0.001). Conclusion Younger age, a non-white ethnicity, fewer eye conditions and poorer self-reported health and visual function are risk factors for significant depressive symptoms in this population. Trial registration number ISRCTN46824140; Pre-results.

6 June 2012 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
TMTom H Margrain
Tom H Margrain
CNClaire Nollett
Claire Nollett
JSJulia Shearn
Julia Shearn
MSMiles Stanford
Miles Stanford
RERhiannon Tudor Edwards
Rhiannon Tudor Edwards
DSDaniel J Smith
Daniel J Smith
The prevalence of depression in people with a visual disability is high but screening for depression and referral for treatment is not yet an integral part of visual rehabilitation service provision. One reason for this may be that there is no good evidence about the effectiveness of treatments in this patient group. This study is the first to evaluate the effect of depression treatments on people with a visual impairment and co morbid depression. The study is an exploratory, multicentre, individually randomised waiting list controlled trial. Participants will be randomised to receive Problem Solving Therapy (PST), a ‘referral to the GP’ requesting treatment according to the NICE’s ‘stepped care’ recommendations or the waiting list arm of the trial. The primary outcome measure is change (from randomisation) in depressive symptoms as measured by the Beck’s Depression Inventory (BDI-II) at 6 months. Secondary outcomes include change in depressive symptoms at 3 months, change in visual function as measured with the near vision subscale of the VFQ-48 and 7 item NEI-VFQ at 3 and 6 months, change in generic health related quality of life (EQ5D), the costs associated with PST, estimates of incremental cost effectiveness, and recruitment rate estimation. Depression is prevalent in people with disabling visual impairment. This exploratory study will establish depression screening and referral for treatment in visual rehabilitation clinics in the UK. It will be the first to explore the efficacy of PST and the effectiveness of NICE’s ‘stepped care’ approach to the treatment of depression in people with a visual impairment. ISRCTN46824140

1 April 2005 in Psychiatric Bulletin
Verified
Journal Article
Open access
PDF file
EBEric J. Button
Eric J. Button
EBElizabeth Benson
Elizabeth Benson
CNClaire Nollett
Claire Nollett
RPRobert L. Palmer
Robert L. Palmer
Aims and Method: The aim of the study was to track service consumption in adult referrals to a specialised NHS eating disorders service over a 3-year period. We examined clinical records of a year's cohort (1999) of 147 referrals (96% female) assessed from the local catchment area.Results: The most common diagnostic group (42.8%) presented with some form of eating disorder not otherwise specified (EDNOS). There was no significant relationship between diagnosis and service consumption, so that full syndrome eating disorders were no more labour-intensive overall than EDNOS patients. Indeed, EDNOS patients accounted for 50% of all outpatient appointments and over a half of all in-patient days.Clinical Implications: The results suggest that those planning services for eating disorders need to take into account the substantial demand from EDNOS patients.